Benny Vittrup Jensen

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Herlev, Copenhagen, Denmark
    Int J Cancer 98:582-9. 2002
  2. ncbi request reprint [Drug therapy of patients with metastatic colorectal cancer]
    Per Pfeiffer
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 167:4261-5. 2005
  3. ncbi request reprint Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Copenhagen, Herlev, Denmark
    Semin Oncol 33:S15-21. 2006
  4. ncbi request reprint Is YKL-40 a new therapeutic target in cancer?
    Julia S Johansen
    Herlev Hospital, University of Copenhagen, Department of Rheumatology Q107, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Expert Opin Ther Targets 11:219-34. 2007
  5. ncbi request reprint Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
    B V Jensen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Ann Oncol 13:699-709. 2002
  6. ncbi request reprint High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer
    Benny Vittrup Jensen
    Department of Oncology, Herlev Hospital, Hvidovre Hospital, University of Copenhagen, DK 2750 Herlev Denmark
    Clin Cancer Res 9:4423-34. 2003
  7. doi request reprint Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    J Nucl Med 54:1026-31. 2013
  8. doi request reprint Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Camilla Qvortrup
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 49:833-6. 2010
  9. ncbi request reprint Serum YKL-40, a new prognostic biomarker in cancer patients?
    Julia S Johansen
    Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Cancer Epidemiol Biomarkers Prev 15:194-202. 2006
  10. doi request reprint Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 51:231-3. 2012

Detail Information

Publications15

  1. ncbi request reprint Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Herlev, Copenhagen, Denmark
    Int J Cancer 98:582-9. 2002
    ..Serum PINP levels may be a diagnostic and prognostic tool that indicate breast cancer activity, aggressiveness, expansion and metastasis and a predictor of outcome after anthracycline-based chemotherapy...
  2. ncbi request reprint [Drug therapy of patients with metastatic colorectal cancer]
    Per Pfeiffer
    Odense Universitetshospital, Onkologisk afdeling R
    Ugeskr Laeger 167:4261-5. 2005
    ..Instead of being a more or less acute life-threatening disease, metastatic colorectal cancer may exist as a chronic condition for years...
  3. ncbi request reprint Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
    Benny Vittrup Jensen
    Department of Oncology, University Hospital of Copenhagen, Herlev, Denmark
    Semin Oncol 33:S15-21. 2006
    ..Further investigation is required into the use of angiotensin-converting enzyme inhibitors to redress cardiac damage and new methods of identifying patients at high risk of congestive heart failure before cardiac damage has occurred...
  4. ncbi request reprint Is YKL-40 a new therapeutic target in cancer?
    Julia S Johansen
    Herlev Hospital, University of Copenhagen, Department of Rheumatology Q107, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Expert Opin Ther Targets 11:219-34. 2007
    ..Drugs inhibiting YKL-40 should be explored as new cancer therapeutics...
  5. ncbi request reprint Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
    B V Jensen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Ann Oncol 13:699-709. 2002
    ..As no prospective studies in a larger series have been performed, these recommendations are based on retrospective data on small numbers of patients...
  6. ncbi request reprint High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer
    Benny Vittrup Jensen
    Department of Oncology, Herlev Hospital, Hvidovre Hospital, University of Copenhagen, DK 2750 Herlev Denmark
    Clin Cancer Res 9:4423-34. 2003
    ....
  7. doi request reprint Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    J Nucl Med 54:1026-31. 2013
    ....
  8. doi request reprint Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Camilla Qvortrup
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 49:833-6. 2010
    ..Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented...
  9. ncbi request reprint Serum YKL-40, a new prognostic biomarker in cancer patients?
    Julia S Johansen
    Department of Rheumatology Q107, Herlev Hospital, Herlev Ringvej 75, DK 2730 Herlev, Denmark
    Cancer Epidemiol Biomarkers Prev 15:194-202. 2006
    ....
  10. doi request reprint Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Finn Ole Larsen
    Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark
    Acta Oncol 51:231-3. 2012
    ..The efficacy and safety of bevacizumab and capecitabine in heavily pre-treated patients with metastatic colorectal cancer were evaluated...
  11. doi request reprint Observer variability in a phase II trial - assessing consistency in RECIST application
    Kristin Skougaard
    Department of Oncology, Copenhagen University Hospital Herlev, Denmark
    Acta Oncol 51:774-80. 2012
    ..To assess the consistency of Response Evaluation Criteria in Solid Tumours (RECIST) application in a phase II trial...
  12. ncbi request reprint [Combined surgical and oncological management of colorectal liver metastases]
    Magnus Bergenfeldt
    Herlev Hospital, Afdelingen for Kirurgisk Gastroenterologi, Herlev
    Ugeskr Laeger 170:1353-6. 2008
    ..Bilateral, multiple and large metastases can also be treated by complex combinations of portal vein embolization/ligature, staged resections and local (radiofrequency) ablation...
  13. ncbi request reprint Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Per Pfeiffer
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Acta Oncol 46:697-701. 2007
    ..Salvage therapy with cetuximab and irinotecan is effective in patients pretreated with irinotecan, and oxaliplatin and in a general population the results from the BOND I study was confirmed...
  14. ncbi request reprint [Treatment of liver and lung metastases from colorectal cancer]
    Flemming Burcharth
    Amtssygehuset i Herlev, Kirurgisk gastroenterologisk afdeling
    Ugeskr Laeger 167:4268-72. 2005
    ....
  15. ncbi request reprint Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports
    Dorte L Nielsen
    Acta Oncol 45:1137-8. 2006